The anti-obesity drugs market is projected to grow from USD 45.1 billion in 2026 to USD 106.5 billion by 2035, at a 10.0% CAGR. Rising obesity rates, GLP-1 therapies, novel drug development.
Anti-Obesity Drugs Market Overview
Anti-obesity drugs, also known as weight loss drugs, comprise a range of pharmaceutical treatments designed to assist individuals in managing obesity and related health conditions. These therapies work through different mechanisms, including appetite regulation, increased satiety, fat absorption and metabolic pathways.
The rising prevalence of obesity and associated conditions such as diabetes and cardiovascular diseases is increasing the demand for effective weight-management therapies. Growing awareness of obesity as a chronic health condition, combined with advancements in pharmaceutical research, has expanded the range of treatment options available to patients.
Anti-obesity medications can complement lifestyle interventions such as diet and exercise and may provide an alternative or adjunct to bariatric surgery for eligible patients. Advances in drug formulation, delivery systems and novel therapeutic mechanisms are also supporting the development of more effective treatment options.
Download Sample Pages of the Anti-Obesity Drugs Market Study:
https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html
Anti-Obesity Drugs Market: Key Highlights
According to the Roots Analysis study:
- The global anti-obesity drugs market is projected to reach USD 106.5 billion by 2035.
- The market is estimated at USD 45.1 billion in 2026.
- The market is expected to expand at a 10.0% CAGR from 2026 to 2035.
- Biologics currently account for close to 55% of the market by type of molecule.
- Prescription drugs represent the largest share by type of drug.
- Tirzepatide currently accounts for more than 45% of the market by active compound.
- GLP-1 agonists hold the largest share by mechanism of action.
- Single agonists currently represent the largest share by type of agonist.
- Centrally acting drugs account for more than 90% of the market by action pathway.
- Parenteral administration currently holds the largest share by route of administration.
- Retail and online pharmacies account for the largest share by distribution channel.
- North America currently represents the largest regional market, accounting for approximately 65% of the market.
- Asia-Pacific is expected to be the fastest-growing region during the forecast period.
Recent Developments in the Anti-Obesity Drugs Market
- In April 2026, Eli Lilly received USFDA approval for Foundayo™ (orforglipron) for adults living with obesity.
- In March 2026, the USFDA approved a higher dose of Wegovy (semaglutide) injection, known as Wegovy HD.
- In January 2026, Roche announced plans to invest approximately USD 2 billion to expand its North Carolina campus, supporting its strategy in the competitive obesity-drug market.
- In August 2025, Teva Pharmaceuticals announced USFDA approval of the first generic version of liraglutide (Saxenda) for weight loss in adults and adolescents with obesity and at least one weight-related comorbid condition.
- Top Anti-Obesity Drugs
Key companies profiled in the market study include:
Adocia
AstraZeneca
Boehringer Ingelheim
CinFina Pharma
Eli Lilly
Gmax Biopharma
Hanmi Pharmaceuticals
Jiangsu Hengrui Pharmaceuticals
Kallyope
NB: The information provided in this press release is for general informational purposes only. PRnob publishes this content as submitted and does not independently verify or endorse the information, claims, products, or services mentioned herein.
